ROFN

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Tuesday, November 14, 2023
CNS, DSM-IV codes, DNA, Conditional sentence, Janssen Pharmaceuticals, Subthalamic nucleus, Patient, Research, ESGCT, FTD, Capsid, Quality control, Congress, I&I, Safety, Treatment, IND, Immunology, Inherited disorders of trafficking, ROFN, Evercore, Genome, STN, Central nervous system, Martin Lipton, Frontotemporal dementia, Xerostomia, Johnson & Johnson, MIA, GMP, Gene, BLA, Commercial, Insurance, Parotid gland, ALS, Parkinson's disease, Clinical trial, Obesity, QC, File, CGMP, RIX, Pharmaceutical industry, Vaccine, Cryptocurrency, Birth control, Sanofi, Janssen, Inflammation

Bota-vec for the Treatment of XLRP:

Key Points: 
  • Bota-vec for the Treatment of XLRP:
    Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
  • Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
  • License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Retrieved on: 
Monday, October 30, 2023
Wachtell, Lipton, Rosen & Katz, DSM-IV codes, Vaccine, Xerostomia, ROFN, CNS, Central nervous system, Evercore, Martin Lipton, I&I, Immunology, Patient, Inflammation, Sanofi

“We are very pleased with this first strategic investment from Sanofi,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

Key Points: 
  • “We are very pleased with this first strategic investment from Sanofi,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.
  • So, we welcome technological innovations that help us chase the scientific miracles of the future.
  • We believe that MeiraGTx’s Riboswitch platform, supported by its unique manufacturing capabilities, is such a technology.
  • is serving as financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to MeiraGTx.

Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
NGS, JD, Depreciation, Doctor of Philosophy, DNA, MBBS, Merck, National Center for Advancing Translational Sciences, General Administration of Press and Publication, Genomics, Metabolism, Investigational New Drug, Workforce, Partnership, IND, IEM, EPI, Terminal deoxynucleotidyl transferase, Exocrine pancreatic insufficiency, Steatorrhea, Mass meeting, Patient, R, Fabry disease, MAI, Enzyme, PKU, Probability, Synthetic biology, ROFN, Serum, Doctor of Science, Takeda Pharmaceutical Company, General counsel, Rhode Island Division of Commercial Licensing and Regulation, Administration, Roche, Cryptocurrency, Pharmaceutical industry, Fine chemical, Video game, Phenylketonuria, Takeda, Fabry, Codexis, Science

REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Total revenues for the fourth quarter 2022 were $30.4 million, an increase of 24% from $24.5 million in the fourth quarter 2021.
  • R&D revenues for the fourth quarter 2022 were $7.1 million compared to $7.5 million in the fourth quarter 2021.
  • Product gross margin for the fourth quarter 2022 was 64% compared to 60% in the fourth quarter 2021, driven by changes in sales mix.
  • Selling, General & Administrative expenses for the fourth quarter 2022 were $12.3 million, compared to $11.7 million in the fourth quarter 2021.